Soluble epoxide hydrolase as a target for ocular diseases
AssigneeIndiana University Research and Technology Corporation
InventorsTimothy William Corson, Rania Sulaiman
Life of this patent
Estimating the term…
Abstract
Methods of using compounds to inhibit ocular disease are disclosed herein. Methods are disclosed for inhibiting soluble epoxide hydrolase (sEH) for the treatment of ocular diseases, and in particular, wet age-related macular degeneration (AMD).
Claims13
A method of inhibiting ocular disease in a subject in need thereof, the method comprising administering to the subject a soluble epoxide hydrolase (sEH) inhibitor selected from the group consisting of 7-(trifluoromethyl)-N-(4-(trifluoromethyl)phenyl) benzo[d]isoxazol-3-amine (7);
- 12-(3-((3s,5s,7s)-adamantan-1-yl)ureido)dodecanoic acid (AUDA);
- sorafenib;
- 1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281);
- (1R,3S)—N-(4-cyano-2-(trifluoromethyl)benzyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexane-1-carboxamide (GSK2256294);
- trans-4-{4-[3-(4-trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid (t-TUCB or UC1728);
- N-[(1S,2R)-2-phenylcyclopropyl]-4-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-)1-piperidinecarboxamide;
- antisense RNA targeting sEH (EPHX2) RNA;
- shRNA targeting sEH (EPHX2) RNA;
- siRNA targeting sEH (EPHX2) RNA;
- RNA silencing targeting sEH (EPHX2) RNA;
- RNA interference (RNAi) targeting sEH (EPHX2) RNA;
- CRISPR/Cas9-mediated genetic ablation of sEH (EPHX2) genomic DNA;
- zinc-finger nuclease-mediated genetic ablation of sEH (EPHX2) genomic DNA;
- and combinations thereof.
A method of treating wet age-related macular degeneration (AMD) in a subject, the method comprising administering to the subject a soluble epoxide hydrolase (sEH) inhibitor selected from the group consisting of 7-(trifluoromethyl)-N-(4-(trifluoromethyl)phenyl) benzo 1M isoxazol-3-amine (7);
- 12-(3-((3s,5s,7s)-adamantan-1-yl)ureido)dodecanoic acid (AUDA);
- sorafenib;
- 1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281);
- (1R,3S)—N-(4-cyano-2-(trifluoromethyl)benzyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexane- 1-carboxamide (GS K2256294);
- trans-4-{4-[3-(4-trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid (t-TUCB or UC1728);
- N-[(1S,2R)-2-phenylcyclopropyl]-4-[3-(2-pyridinyl)-1,2,4-oxadiazo 1-5-yl]-)1-piperidinecarboxamide;
- antisense RNA targeting sEH (EPHX2) RNA;
- shRNA targeting sEH (EPHX2) RNA;
- siRNA targeting sEH (EPHX2) RNA;
- RNA silencing targeting sEH (EPHX2) RNA;
- RNA interference (RNAi) targeting sEH (EPHX2) RNA;
- CRISPR/Cas9-mediated genetic ablation of sEH (EPHX2) genomic DNA;
- zinc-finger nuclease-mediated genetic ablation of sEH (EPHX2) genomic DNA;
- and combinations thereof.
Dependencies are inferred from the claim text.